Check for updates

OPEN ACCESS

EDITED BY Félix Javier Jiménez-Jiménez, Hospital Universitario del Sureste, Spain

REVIEWED BY Yueshu Zhao, Third Affiliated Hospital of Zhengzhou University, China Qiheng He, Capital Medical University, China

*CORRESPONDENCE Junqiang Ma ⊠ 736247781@gg.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 30 November 2023 ACCEPTED 02 February 2024 PUBLISHED 14 February 2024

CITATION

Wu J, Sun H and Ma J (2024) Causal association between depression and intracranial aneurysms: a bidirectional two-sample Mendelian randomization study. *Front. Neurol.* 15:1346703. doi: 10.3389/fneur.2024.1346703

COPYRIGHT

© 2024 Wu, Sun and Ma. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Causal association between depression and intracranial aneurysms: a bidirectional two-sample Mendelian randomization study

Jujiang Wu^{1†}, Hao Sun^{1†} and Jungiang Ma^{1,2*}

¹Neurointensive Care Unit, The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ²Department of Population Medicine, Shantou University Medical College, Shantou, China

Background: Although observational studies have suggested a bidirectional relation between depression and intracranial aneurysms (IAs), their causal relations remain unclear. Thus we aimed to assess the causal association between depression and IAs.

Methods: We conducted a bidirectional two-sample Mendelian randomization (MR) study using summary-level data from publicly available genome-wide association studies of depression (n = 500,199), IAs (n = 79,429), unruptured intracranial aneurysm (uIA) (n = 74,004), and subarachnoid hemorrhage (SAH) (n = 77,074). MR analyses included the inverse-variance weighted (IVW) method as the primary analytic, plus weighted-median, simple mode, weighted mode, MR-Egger, and MR PRESSO.

Results: Genetically predicted depression was strongly positively related to IAs (odds ratio [OR] = 1.69, 95% confidence interval [CI] 1.19–2.39, p = 0.003), uIA (OR = 1.96, 95% CI 1.06–3.64, p = 0.032), and SAH (OR = 1.73, 95% CI 1.14–2.61, p = 0.009). Reverse MR analyses showed that while genetically predicted uIA was positively related to depression (OR = 1.02, 95% CI 1.00–1.05, p = 0.044), no causal relations were observed for either IAs or SAH for depression.

Conclusion: Our findings provide evidence of a causal effect of depression on IAs, uIA, and SAH. For the reverse MR analyses, we found a causal impact of uIA on depression, but no causal influence of either IAs or SAH for depression.

KEYWORDS

causal association, depression, intracranial aneurysms, subarachnoid hemorrhage, Mendelian randomization

1 Introduction

Intracranial aneurysm (IA), localized pathological dilations at major bifurcations of cerebral arteries, is characterized by internal elastic lamina loss and media disruption (1). In a global study of individuals with a mean age of 50 years, IA incidence was ~3.2% (2). IAs are susceptible to rupture, which causes ~85% of spontaneous subarachnoid hemorrhage (SAH) (3). Poor prognosis and high death and disability rates are common features of aneurysmal

SAH (4, 5). Consequently, it is important to pinpoint the causes of IA development to launch early, targeted interventions.

Depression is a primary cause of disability, accounting for over 300 million cases globally (6). Those with depression are at increased risk for a host of medical conditions in later life (7). Observational studies have shown a connection between IA and depression (8–10). For instance, a nine-year cohort study by Marijnissen et al. revealed depression to be a stroke (including IA) risk factor (11). However, as has been frequently noted, these observational studies have been limited by confounding factors and reverse causality. Because development of both depression and IA have vague, subtle onsets, it is challenging to establish their temporal order. One study revealed a lack of genetic support for a causal relation between major depressive disorder and IA (12), possibly because of confounding factors and differences in data sources. There has also been insufficient evidence to determine the direction of such causality (12); thus, the potential causality of depression in IA risk, and vice versa, has remained elusive.

Mendelian randomization (MR), which uses genetic variation in non-experimental data to identify causal relations between exposure and outcome, can lessen the statistical influence of social, behavioral, psychological, and other factors (13). By utilizing genome-wide association study (GWAS) summary statistics, MR studies have emerged as a powerful, effective tool for determining causal relations between exposure and outcome phenotypes (14, 15). Using single nucleotide polymorphisms (SNPs) extracted as instrumental variables (IVs) from a GWAS, a two-sample MR analysis can be used to determine causal links between two traits (16). Herein, we analyzed the causal relations between depression and IAs with two-sample MR with recently published GWAS summary data for depression and IAs.

2 Methods

To assess the causal association between depression and IAs, we performed a bidirectional two-sample MR analysis for each exposure–outcome pair. All GWAS summary data analyzed herein are publicaly available. All included studies obtained ethical approval and informed consent. Figure 1 shows a brief description of this bidirectional MR design. Summary GWAS data for depression and IAs were assembled from published studies using samples from the most significant European populations (Table 1).

2.1 Genetic instrument selection for MR analyses

The three major MR assumptions were used to filter the SNPs for each exposure factor. For assumption 1, we performed the following three steps. First, SNPs that met a threshold for genome-wide significance ($p < 5 \times 10^{-8}$) and were associated with the exposure were included as IVs. Second, based on linkage disequilibrium (LD) as determined by r^2 and window size (when $r^2 < 0.001$ and window size = 10,000 kb in the European 1,000 Genome reference panel), we retained variations with the lowest *p*-values as independent instruments. Third, we calculated F-statistics to quantify the power of IVs; F-statistics >10 is commonly advised for MR analysis. For assumption 2, the IVs did not include SNPs that were significantly ($p < 1 \times 10^{-5}$) linked to confounders. We controlled for confounding factors, including body mass index, alcohol intake frequency, and smoking (Supplementary Table S1). For assumption 3, SNPs related to outcomes were eliminated from the IVs.

2.2 Depression data

The three largest GWAS including various depression phenotypes from 23andMe, PGC, and UK Biobank were included in the depression meta-analysis by Howard et al. (17). However, in only PGC and UK Biobank are the meta-analyses of depression summary statistics for all assessed variants publicly available; these are based on 170,756 cases and 329,443 controls, all of whom are of European ancestry. Therefore, the primary analysis herein examined the association between depression and IAs based on 500,199 individuals with depression, as defined by the PGC and UK Biobank metaanalyses. Using the $p < 5 \times 10^{-8}$ threshold, 20 SNPs were found to be associated with depression for IVs (Supplementary Table S2). The reverse-direction MR analyses also used the summary-level PGC and UK Biobank data for 500,199 individuals.

2.3 IAs, uIA and SAH data

Summary statistics IAs data among individuals of European ancestry originated from a GWAS of 23 different cohorts, comprised of 7,495 cases and 71,934 controls (18). Within these, 4,471,083 SNPs met the quality control standards. Among these, there were 69% with ruptured IAs, 28% with unruptured IA (uIA), and 3.8% with unknown rupture status; specifically, there were 5,140 SAH (i.e., ruptured IA) cases and 2,070 unruptured IAs cases of European ancestry. Therefore, the MR analyses herein used the three summary datasets, all including individuals of European ancestry, separately: GWAS of IAs (unruptured and ruptured) cases (n=7,495) vs. controls (n=71,934); GWAS of unruptured IA-only cases (n=2,070) vs. controls (n=71,934); and GWAS of SAH-only cases (n=5,140) vs. controls (n=71,934). For reverse MR analyses, since few SNP-IA associations met the genomewide association threshold (i.e., $p < 5 \times 10^{-8}$), a suggestive level of significance $(p < 1 \times 10^{-6})$ was used to extract IVs. Eight independent genetic SNPs associated with IAs (Supplementary Table S3), 4 SNPs associated with uIA (Supplementary Table S4), and 8 SNPs associated with SAH (Supplementary Table S5) were identified at this genomewide significance level.

2.4 MR analysis

Herein, R^2 was the proportion of variance in an exposure factor explained by each IV, and the F-statistic was calculated to measure the strength of each IV (19). The F-statistic used the following formula: $F=R^2$ (N-2) / ($1-R^2$), where N= the GWAS sample size for the exposure association.

MR analyses used the random-effects inverse-variance weighted (IVW) method as the primary analysis to assess the potential bidirectional causal relations between depression and IAs, because it gives a reliable causal estimate in the absence of directional pleiotropy (20). We also performed sensitivity analyses using weighted median, simple mode, weighted mode, MR-Egger, and MR-PRESSO. These



TABLE 1 GWAS data details.

Phenotype	Total sample size	Cases, n	Controls, <i>n</i>	Population	Consortium	PMID
Depression	500,199	170,756	329,443	European	Howard et al.	30718901
IAs	79,429	7,495	71,934	European	Bakker et al.	33199917
uIA	74,004	2,070	71,934	European	Bakker et al.	33199917
SAH	77,074	5,140	71,934	European	Bakker et al.	33199917

IAs, intracranial aneurysms; uIA, unruptured intracranial aneurysm; SAH, subarachnoid hemorrhage.

robust analytics provide valid causal inferences under weaker assumptions than does the standard IVW (21, 22). The intercept of MR-Egger (23) and the global test from MR-PRESSO (24) were used to assess horizontal pleiotropy. To detect and correct horizontal pleiotropic outliers, we also used the MR pleiotropy residual sum and outlier (MR-PRESSO) approach (24). We assessed potential heterogeneity with Cochran's Q (25). Leave-one-out analysis was conducted by sequentially excluding each SNP, and an IVW approach was applied to the remaining SNPs to determine whether a specific variant would impact the estimations. MR results are presented as odds ratios (OR) of the outcome risk for the corresponding unit changes in exposure, and 95% confidence intervals (CI).

All statistical analyses were performed using R (v4.3.1) statistical software. R package TwoSampleMR was used to perform MR analyses.

3 Results

3.1 Causal effects of depression on IAs, uIA, and SAH

MR analyses of the causal effect of depression on IAs, uIA, and SAH, and pleiotropy effect assessments, are presented in Table 2.

Supplementary Figures S1A–C shows scatter plots of the causal connections between depression and IAs, uIA, and SAH, with colored lines denoting the slopes of each regression analysis. In the scatter plots, each point represents a IV SNP, and lines of different colors represent different MR analysis methods. Results shown in the three scatter plots indicate that the lines representing different MR analysis methods generally slope upwards, suggesting that as depression increases, risk of developing IAs, uIA, and SAH increases. Forest plots (Figure 2) show MR estimates for the effects of the SNPs related to depression on IAs, uIA, and SAH. In the forest plots, each solid horizontal line represents a single SNP; because of the lack of robustness of the individual SNP results, it was necessary to integrate them (combined red line at bottom). The red lines below the three forest plots indicate that an increase in depression can increase the risk of IAs, uIA, and SAH.

There were no weak IVs, as each F-statistic was not <30. Genetically predicted depression was strongly positively related to IAs, uIA, and SAH. With 20 genetic instruments in the major analysis, the IVW method demonstrated that genetically doubling the odds of depression increased the risk of IAs, SAH, and uIA by 69, 73, and 96%, respectively (IAs: OR=1.69, 95% CI 1.19–2.39, p=0.003; SAH: OR=1.73, 95% CI 1.14–2.61, p=0.009; uIA: OR=1.96, 95% CI 1.06–3.64, p=0.032). MR-Egger regression showed no horizontal pleiotropy

Depression	IVW		М	R-Egger	MR PRESSO (outlier-corrected)			
	OR (95% CI)	Q (p value)	OR (95% CI)	Intercept (p value)	Outlier	OR (95%CI)	p for global test	
IAs	1.69 (1.19, 2.39)	12.5 (0.86)	1.36 (0.03, 6.08)	0.0 (0.91)	0	NA	0.88	
SAH	1.73 (1.14, 2.61)	13.9 (0.79)	2.91 (0.03, 2.60)	0.0 (0.79)	0	NA	0.82	
uIA	1.96 (1.06, 3.64)	15.0.5 (0.69)	0.08 (0.0, 6.83)	0.09 (0.69)	0	NA	0.70	

TABLE 2 Effect estimates of associations between genetic instrumental variables for depression and aneurysm risk.

IAs, intracranial aneurysms; uIA, unruptured intracranial aneurysm; SAH, subarachnoid hemorrhage; OR, odds ratio; 95% CI, 95% confidence interval; Q, Cochran's Q; NA, not applicable.



in the analysis of the causal effect of depression on IAs, SAH or uIA (IAs: egger_intercept=0.0, p=0.91; SAH: egger_intercept=0.0, p=0.79; uIA: egger_intercept=0.09, p=0.69). Nor was horizontal pleiotropy found in the MR-PRESSO global test (IAs: p=0.88; SAH: p=0.82; uIA: p=0.70) and MR-PRESSO failed to find any notable outliers. Cochran's *Q* indicated no significant heterogeneities (IAs: Q=12.5, p=0.86; SAH: Q=13.9, p=0.79; uIA: Q=15.5, p=0.69); this is shown in the funnel plots (Supplementary Figures S2A–C), on which points on either side of the IVW line are roughly symmetrical. The leave-one-out test revealed that the causal estimate was not driven by any single SNP (Supplementary Figures S3A–C); that the overall error line does not change significantly after excluding each SNP indicates reliable results.

3.2 Causal effects of IAs, SAH, and uIA on depression

Results of the reverse MR analysis of the causal effect of IAs, SAH, and uIA on depression and the evaluation of pleiotropic effects are in Table 3. We also created scatter and forest plots for each pair of associations (Supplementary Figures S1D–F; Figure 3). MR results showed that only uIA was causally associated with depression in the IVW models (OR=1.02, 95% CI 1.00–1.05, p = 0.044), which was positively associated with depression. No significant relations were

found for IAs or SAH (IAs: OR = 1.01, 95% CI 0.99–1.04, p = 0.288; SAH: OR = 1.00, 95% CI 0.97–1.05, p = 0.667). Regarding the causal relations between uIA or SAH and depression, no horizontal pleiotropy was detected in the MR-Egger regression (uIA: egger_ intercept = 0.0, p = 0.89; SAH: egger_intercept = 0.0, p = 0.92) or the MR-PRESSO global test (uIA: p = 0.43; SAH: p = 0.06). For the causal relation between IAs and depression, while MR-Egger regression suggested no horizontal pleiotropy (egger_intercept = 0.0, p = 0.64), MR-PRESSO found evidence of pleiotropy (p = 0.03). MR-PRESSO did not show any significant outliers of horizontal pleiotropy. Cochran's Q and funnel plots (Supplementary Figures S2D–F) indicated no heterogeneities, except for the relation between SAH and depression risk. Leave-one-out analyses showed no significant SNPs aside from those for uIA (Supplementary Figures S3D–F).

4 Discussion

Herein, we assessed the causal relations between depression and IAs. Two-sample bidirectional MR analyses detected that genetic propensity for depression was positively associated with IAs, SAH, and uIA risks. Reverse MR analyses showed that only genetic link to uIA was associated with increased depression risk. No evidence was found to indicate a genetic link with either IAs or SAH in association with depression.

IAs	IVW		MR-Egger		MR PRESSO (outlier-corrected)			
	OR (95% CI)	Q (p value)	OR (95% CI)	Intercept (p value)	Outlier	OR (95% CI)	<i>p</i> for global test	
Depression	1.01 (0.99, 1.04)	13.3 (0.06)	1.05 (0.93, 1.18)	0.0 (0.64)	0	NA	0.03	
SAH	IVW		MR-Egger		MR PRESSO (outlier-corrected)			
	OR (95% CI)	Q (p value)	OR (95% CI)	Intercept (p value)	outlier	OR (95% CI)	p for global test	
Depression	1.00 (0.97, 1.05)	11.3 (0.02)	1.02 (0.80, 1.30)	0.0 (0.92)	0	NA	0.06	
					1			
ulA	IVW		MR-Egger		MR PRESSO (outlier-corrected)			
	OR (95% CI)	Q (p value)	OR (95% CI)	Intercept (p value)	Outlier	OR (95% CI)	<i>p</i> for global test	
Depression	1.02 (1.00, 1.05)	3.5 (0.32)	0.98 (0.53, 1.81)	0.0 (0.89)	0	NA	0.43	

TABLE 3 Effect estimates of associations between genetic instrumental variables for aneurysm and depression risk.

IAs, intracranial aneurysms; uIA, unruptured intracranial aneurysm; SAH, subarachnoid hemorrhage; OR, odds ratio; 95% CI, 95% confidence interval; Q. Cochran's Q: NA, not applicable.



Forest plots of causal effects of IAs, uIA, and SAH on depression. IAs, intracranial aneurysms; uIA, unruptured intracranial aneurysm; SAH, subarachnoid hemorrhage; IVs, instrumental variables; IVW, inverse-variance weighted; MR, Mendelian randomization; OR, odds ratio; 95% CI, 95% confidence interval.

Observational studies have revealed bidirectional correlations between depression and IAs. Marijnissen et al. discovered that depression is a risk factor for IAs (11), consistent with our results. Individuals diagnosed with depression exhibit a 43% elevated risk of stroke and have an average two-point higher National Institutes of Health Stroke Scale score than do those without pre-stroke depression (26, 27). Pre-stroke depression is likely a substantial modifiable risk factor for post-stroke depression and functional impairment (28, 29). A meta-analysis of a cumulative ~700,000 participants by Barlinn et al. found that depression increases the risk of first-ever stroke by 40% in the general population (26). A further registry study reported evidence of an association between hospitalization for depression and subsequent stroke (30). Pharmacological interferences with platelet aggregation caused by antidepressant medication may increase stroke risk in those with depression (31). Hypothalamic-pituitary-adrenal (HPA) axis dysregulation related to stress and depression may increase

circulating catecholamines, endothelial dysfunction, and platelet activation, resulting in a hypercoagulable condition and raising stroke risk (32, 33). Previous studies have also suggested that depression has unique underlying cerebral pathomechanisms, including cerebral inflammation, HPA axis dysregulation, increased platelet reactivity, and autonomic dysfunction (34). The causal relations between depression and IAs, uIA, and SAH herein thus reinforce the notion that depression prevention and early diagnosis may help prevent IAs, uIA, and SAH. The distinct clinical prognosis of uIA and SAH suggest that alleviating depression may reduce IAs rupture risk, particularly in patients with uIA in whom long-term observation or watchful waiting is preferred over surgical intervention. However, the exact mechanisms underlying the causal association between depression and IAs remains unclear. Subsequent studies should thus concentrate on the specific mechanisms mediating these associations, and on pharmacological treatments for depression.

Regarding the reverse direction, living with uIA without treatment may lower quality of life and lead to mental health issues like anxiety and depression (35, 36). Chinese patients with untreated uIA tend to suffer from short-term depression, anxiety, and reduced quality of life after diagnosis (37). These findings are consistent with our study results showing that uIA is positively related to depression risk. Patients diagnosed with uIA may develop depression from concerns about the uIA rupturing. In patients with uIA, rupture risk is the most apparent cause of preoperative anxiety and depression (37). Recent studies emphasize the significance of psychological factors and quality of life in uIA management strategies (38, 39). Our findings support the notion that attending to the occurrence of depression in patients with uIA is warranted. Furthermore, long-term depressive symptoms persist after SAH in 72% of patients (40). Depression after stroke is generally considered a chronic illness, with prevalence and incidence of ~30% and ~15%, respectively, for 1-15 years post-stroke (41). After SAH, up to one in three patients may develop pituitary dysfunction (42), which may facilitate development of depression (43). Patients with depression after SAH also have lower basal cortisol levels (44). Yet our MR analyses revealed no evidence of support for causal effects of IAs or SAH on depression, indicating that the previously observed associations may be due to confounds. Studies of the development of depression after SAH have found that comorbid cognitive impairment, fatigue, post-traumatic stress disorder, and physical disability increase depression risk (9).

This study had several major strengths. First, it is the first two-sample MR study to identify a causal effect between depression and IAs, allowed by genotype-based random distribution. Second, this design avoids the possible effects of reverse causation and potential confounding factors in conventional studies, allowing investigation of causal relations. Third, each exposure had an F-statistic >10, indicating an absence of weak instrument bias. Finally, we tested MR model assumptions through several primary sensitivity analyses.

Several limitations must also be acknowledged. First, our results were derived only from populations of European ancestry; it is therefore essential to exercise caution when applying them to non-European populations, as environment and ethnicity may influence these relations. Second, a relatively small number of strongly correlated SNPs were selected for MR analysis of reverse causality; invalid results may be due to deficient SNPs, which would limit our ability to identify genuine causal relations. Third, not all SNPs were examined; some may have been removed due to LD, potentially impacting the results. Finally, as is true of nearly all MR analyses, it is possible that the IV SNPs we used were related to unmeasured confounders.

5 Conclusion

These two-sample bi-directional MR analyses of depression and IAs, based on large-scale GWAS summary statistics, provide strong evidence of a causal association between depression and IAs, including IAs, SAH, and uIA. Reverse MR analyses support a causal effect of uIA on depression, though not of IAs or SAH on depression. These findings support the recommendation that depression prevention and treatment may mitigate IAs occurrence and progression, and that depression should be closely monitored among patients diagnosed with uIA.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and the institutional requirements.

Author contributions

JW: Writing – original draft, Writing – review & editing. HS: Writing – original draft, Writing – review & editing. JM: Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

We gratefully acknowledge all study participants and staff associated with the GWAS studies we used for this MR study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2024.1346703/ full#supplementary-material

References

1. Chalouhi N, Hoh BL, Hasan D. Review of cerebral aneurysm formation, growth, and rupture. *Stroke.* (2013) 44:3613–22. doi: 10.1161/STROKEAHA.113.002390

2. Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. *Lancet Neurol.* (2011) 10:626–36. doi: 10.1016/S1474-4422(11)70109-0

3. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. *Lancet*. (2017) 389:655–66. doi: 10.1016/S0140-6736(16)30668-7

4. Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0-5 million Chinese adults. *Lancet Glob Health*. (2020) 8:e580–90. doi: 10.1016/S2214-109X(20)30069-3

5. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol.* (2009) 8:635–42. doi: 10.1016/S1474-4422(09)70126-7

6. Nomura S, Sakamoto H, Glenn S, Tsugawa Y, Abe SK, Rahman MM, et al. Population health and regional variations of disease burden in Japan, 1990–2015: a systematic subnational analysis for the global burden of disease study 2015. *Lancet.* (2017) 390:1521–38. doi: 10.1016/S0140-6736(17)31544-1

 Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Børglum AD, Christensen MK, et al. Association between mental disorders and subsequent medical conditions. N Engl J Med. (2020) 382:18, 1721–1731. doi: 10.1056/NEJMoa1915784

8. Henderson KM, Clark CJ, Lewis TT, Aggarwal NT, Beck T, Guo H, et al. Psychosocial distress and stroke risk in older adults. *Stroke*. (2013) 44:367–72. doi: 10.1161/STROKEAHA.112.679159

9. Tang WK, Wang L, Kwok Chu Wong G, Ungvari GS, Yasuno F, Tsoi KKF, et al. Depression after subarachnoid hemorrhage: a systematic review. *J Stroke*. (2020) 22:11–28. doi: 10.5853/jos.2019.02103

10. Zhai XD, Yu JX, Ma YJ, Xiang SS, Li GL, He C, et al. Prevalence of and risk factors for anxiety and depression in Chinese patients with unruptured intracranial aneurysms treated by endovascular intervention. *BMC Psychiatry*. (2020) 20:430. doi: 10.1186/s12888-020-02834-3

11. Marijnissen RM, Wouts L, Schoevers RA, Bremmer MA, Beekman ATF, Comijs HC, et al. Depression in context of low neuroticism is a risk factor for stroke: a 9-year cohort study. *Neurology*. (2014) 83:1692–8. doi: 10.1212/WNL.00000000000055

12. Peng P, Chen Z, Zhang X, Guo Z, Dong F, Xu Y, et al. Investigating causal relationships between psychiatric traits and intracranial aneurysms: a bi-directional two-sample Mendelian randomization study. *Front Genet.* (2021) 19:741429. doi: 10.3389/fgene.2021.741429

13. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet.* (2014) 23:R89–98. doi: 10.1093/hmg/ddu328

14. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med.* (2016) 35:1880–906. doi: 10.1002/sim.6835

15. Dalbeth N, Topless R, Flynn T, Cadzow M, Bolland MJ, Merriman TR. Mendelian randomization analysis to examine for a causal effect of urate on bone mineral density. *J Bone Miner Res.* (2015) 30:985–91. doi: 10.1002/jbmr.2434

16. Davey Smith G, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease?*. *Int J Epidemiol.* (2003) 32:1–22. doi: 10.1093/ije/dyg070

17. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci.* (2019) 22:343–52. doi: 10.1038/s41593-018-0326-7

18. HUNT All-In Stroke, China Kadoorie Biobank Collaborative Group, BioBank Japan Project Consortium, The ICAN Study Group, CADISP Group, Genetics and Observational Subarachnoid Haemorrhage (GOSH) Study investigators et al. Genomewide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. *Nat Genet.* (2020) 52:1303–13. doi: 10.1038/ s41588-020-00725-7

19. Burgess S, Thompson SG. CRP CHD genetics collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol.* (2011) 40:755–64. doi: 10.1093/ije/dyr036

20. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. (2013) 37:658–65. doi: 10.1002/gepi.21758

21. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* (2019) 4:186. doi: 10.12688/wellcomeopenres.15555.1

22. Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. *Genet Epidemiol.* (2020) 44:313–29. doi: 10.1002/gepi.22295

23. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. *Int J Epidemiol.* (2015) 44:512–25. doi: 10.1093/ije/dyv080

24. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet*. (2018) 50:693–8. doi: 10.1038/s41588-018-0099-7

25. Hemani G, Bowden J, Davey SG. Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Hum Mol Genet*. (2018) 27:R195–208. doi: 10.1093/ hmg/ddy163

26. Barlinn K, Kepplinger J, Puetz V, Illigens B, Bodechtel U, Siepmann T. Exploring the risk-factor association between depression and incident stroke: a systematic review and meta-analysis. *Neuropsychiatr Dis Treat*. (2014):1–14. doi: 10.2147/NDT.S63904

27. Naess H, Lunde L, Brogger J, Waje-Andreassen U. Depression predicts unfavourable functional outcome and higher mortality in stroke patients: the Bergen stroke study: depression and stroke. *Acta Neurol Scand.* (2010) 122:34–8. doi: 10.1111/j. 1600-0404.2010.01373.x

28. Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, Jorge RE, Kissela BM, et al. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. (2017) 48:e30–43. doi: 10.1161/STR.00000000000113

29. Aron AW, Staff IFortunato G, McCullough LD. Prestroke living situation and depression contribute to initial stroke severity and stroke recovery. *J Stroke Cerebrovasc Dis.* (2015) 24:492–9. doi: 10.1016/j.jstrokecerebrovasdis.2014.09.024

30. Nilsson FM, Kessing LV. Increased risk of developing stroke for patients with major affective disorder: a registry study. *Eur Arch Psychiatry Clin Neurosci.* (2004) 254:387–91. doi: 10.1007/s00406-004-0519-9

31. Chen V, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. *Ann Pharmacother*. (2008) 42:177–84. doi: 10.1345/aph.1K369

32. Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: recent and emerging concepts. *Lancet Neurol.* (2008) 7:341–53. doi:10.1016/S1474-4422(08)70061-9

33. Elkind MS. Why now? Moving from stroke risk factors to stroke triggers. CurrOpin Neurol. (2007) 20:51–7. doi: 10.1097/WCO.0b013e328012da75

34. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC Med.* (2013) 11:129. doi: 10.1186/1741-7015-11-129

35. Yoshimoto Y, Tanaka Y. Risk perception of unruptured intracranial aneurysms. *Acta Neurochir.* (2013) 155:2029–36. doi: 10.1007/s00701-013-1829-3

36. Bonares MJ, Oliveira Manoel AL, Macdonald RL, Schweizer TA. Behavioral profile of unruptured intracranial aneurysms: a systematic review. *Ann Clin Transl Neurol.* (2014) 1:220–32. doi: 10.1002/acn3.41

37. Su SH, Xu W, Hai J, Yu F, Wu YF, Liu YG, et al. Cognitive function, depression, anxiety and quality of life in Chinese patients with untreated unruptured intracranial aneurysms. *J Clin Neurosci.* (2014) 21:1734–9. doi: 10.1016/j.jocn.2013.12.032

38. Li Y, Dai W, Zhang J. Anxiety, depression and quality of life in patients with a treated or untreated unruptured intracranial aneurysm. *J Clin Neurosci.* (2017) 45:223–6. doi: 10.1016/j.jocn.2017.07.019

39. de Wilde A, Greebe P, Rinkel GJE, Algra A. Stress in patients with (un)ruptured intracranial aneurysms vs population-based controls. *Neurosurgery*. (2019) 84:1065–71. doi: 10.1093/neuros/nyy143

40. Ackermark PY, Schepers VP, Post MW, Rinkel GJ, Passier PE, Visser-Meily JM. Longitudinal course of depressive symptoms and anxiety after aneurysmal subarachnoid hemorrhage. *Eur J Phys Rehabil Med.* (2017) 53:98–104. doi: 10.23736/S1973-9087.16.04202-7

41. Ayerbe L, Ayis S, Crichton S, Wolfe CDA, Rudd AG. The natural history of depression up to 15 years after stroke: the South London Stroke Register. *Stroke.* (2013) 44:1105–10. doi: 10.1161/STROKEAHA.111.679340

42. Vespa PThe participants in the international multi-disciplinary consensus conference on the critical Care Management of Subarachnoid Hemorrhage. Endocrine function following acute SAH. *Neurocrit Care*. (2011) 15:361–4. doi: 10.1007/s12028-011-9587-7

43. Plotsky PM, Owens MJ. Psychoneuroendocrinology of depression. Hypothalamicpituitary-adrenal axis. *Psychiatr Clin North Am.* (1998) 21:293–307. doi: 10.1016/ s0193-953x(05)70006-x

44. Kreitschmann-Andermahr I, Poll E, Hutter BO, Reineke A, Kristes S, Gilsbach JM, et al. Quality of life and psychiatric sequelae following aneurysmal subarachnoid haemorrhage: does neuroendocrine dysfunction play a role? *Clin Endocrinol.* (2007) 66:833–7. doi: 10.1111/j.1365-2265.2007.02821.x